Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study
Journal of Antimicrobial Chemotherapy2015Vol. 70(6), pp. 1881–1884
Citations Over Time
Paul Loubet, Charlotte Charpentier, Benoît Visseaux, Abraham Borbor, Cecilia Nuta, Eric Adu, Jean-Marc Chapplain, Maima Baysah, Pierre Tattevin, Yazdan Yazdanpanah, Diane Descamps
Abstract
The high prevalence of acquired drug resistance in patients followed in two centres of the Liberian capital city, documented after a median of 3 years on a first-line ART regimen, jeopardizes the activity of second-line regimens and highlights the need for virological monitoring in these settings.
Related Papers
- → Crystal Structures of HIV-1 Reverse Transcriptase with Etravirine (TMC125) and Rilpivirine (TMC278): Implications for Drug Design(2010)224 cited
- → Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Review of Its Use in HIV Infection(2014)7 cited
- → Rilpivirine and Etravirine resistance among HIV-1 infected patients failing first generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) in Busia, Western Kenya(2021)1 cited
- → Non‐Nucleoside HIV Reverse Transcriptase Inhibitors for the Treatment of HIV/AIDS: Design and Development of Etravirine and Rilpivirine(2014)
- → Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen in HIV-1 infection: a guide to its use in the EU(2015)